KQEDThe largest union of nurses in California starts contract negotiations Thursday with Kaiser Permanente's hospitals. Talks went smoothly four years ago, but this round will likely be more contentious.
As spending on care rises, the business of health keeps getting more important. We feature news on and analysis of drugmakers, health insurers, hospitals, doctors and others in the business of providing health care.
KHNAlthough medical costs will increase as the economy improves, the shift of expenses to workers by employers will help restrain the overall cost of care a little.
OPBDrugmakers offer medicines at a bargain price to hospitals that treat large numbers of poor patients. Hospitals sometimes resell the drugs at full price and make hefty profits.
ProPublicaMedicare data show a pattern of problematic payments to doctors with a history of disciplinary action. Yet state medical boards don't usually look at billing as a trigger for investigations.
There's a gold rush on in health information technology. Entrepreneurs and venture capitalists are betting on companies that aim to help consumers, insurers and providers save money.
ProPublicaThe Garden State costs Medicare more than any other state for ambulance rides per kidney dialysis patient. A crackdown is set to start, but at one big dialysis center, ambulances remain everywhere.
KHNA recent IRS rule bars employers from offering workers tax-free subsidies to buy policies. But a company could still cancel its plan and leave workers to buy individual policies on the marketplaces.
WCPNSize does matter under the Affordable Care Act. Large companies such as Cleveland's Sherwin-Williams aren't likely to use the individual insurance marketplaces, but they will help pay for them.
The government recently released a trove of information on how much doctors are charging Medicare. It does seem like some doctors are overcharging, but the explanation of high fees can be complicated.
The Food and Drug Administration's approval of a new drug for leishmaniasis came with a voucher that can be redeemed to speed up the approval of a much more lucrative drug in the future.